banner

News Releases

None | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
Date Title
12/20/18
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
11/30/18
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/27/18
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
11/26/18
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
11/06/18
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
10/31/18
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
10/29/18
ACADIA Pharmaceuticals Announces Executive Leadership Change
10/23/18
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
09/26/18
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
09/25/18
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
09/20/18
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
09/10/18
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
09/04/18
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
08/08/18
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
08/06/18
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
07/30/18
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
07/19/18
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
06/29/18
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
06/13/18
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
06/06/18
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
05/08/18
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
05/04/18
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
05/02/18
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
05/01/18
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
04/27/18
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
04/27/18
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
04/23/18
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
03/20/18
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
03/06/18
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
02/27/18
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
02/20/18
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
01/02/18
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018